Monthly SOM230C for Recurrent or Progressive Meningioma

This study is ongoing, but not recruiting participants.
Brigham and Women's Hospital
Massachusetts General Hospital
Beth Israel Deaconess Medical Center
Memorial Sloan-Kettering Cancer Center
Wake Forest Baptist Health
Duke University
Cedars-Sinai Medical Center
Northwestern University
Information provided by (Responsible Party):
Patrick Y. Wen, MD, Dana-Farber/Brigham and Women's Cancer Center Identifier:
First received: March 9, 2009
Last updated: October 29, 2013
Last verified: October 2013

The purpose of this research study is to evaluate the effectiveness and safety of SOM230C in treating recurrent meningiomas. SOM230C is a newly discovered drug that may stop meningioma cells from growing abnormally. This drug has been used in treatment of other tumors, and information from those other research studies suggests that SOM230C may help to stop the growth of meningiomas.

Condition Intervention Phase
Drug: SOM230C
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Study of Monthly SOM230C for Recurrent or Progressive Meningioma

Resource links provided by NLM:

Further study details as provided by Dana-Farber Cancer Institute:

Primary Outcome Measures:
  • To determine the activity of pasireotide LAR monotherapy as measured by PFS6, in patients with recurrent or progressive meningiomas [ Time Frame: 6 mths ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To establish the response rate, median PFS, median overall survival, and time to progression in this population [ Time Frame: 3 years ] [ Designated as safety issue: No ]
  • To characterize the safety and tolerability of pasireotide LAR [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 40
Study Start Date: March 2009
Estimated Study Completion Date: February 2014
Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: SOM230C
    Injection in the buttocks every 28 days
    Other Name: pasireotide LAR
Detailed Description:
  • To enroll in the study, a sample of the participant's tumor tissue, stored from an earlier study, must be sent to a lab at the Dana-Farber/Harvard Cancer Center for diagnosis and special testing.
  • Prior to starting the study medication, participants will undergo a Octreotide scan. This is a special type of scan used to obtain information about certain tumors.
  • Participants will receive the study medication, SOM230C, via an injection into the buttocks every 28 days. Therefore, each treatment cycle lasts 28 days.
  • The following tests and procedures will be done prior to the first, second and third treatment cycles, and every three treatment cycles thereafter: Complete physical examination including neurological exam; vital signs; current medication and symptom review; blood samples and a pregnancy test (for women of child-bearing potential).
  • About 2/3 through the first treatment cycle (around day 22), participants will visit the research doctor for a complete physical examination including a neurological exam and blood work.
  • Participants will have ECGs done prior to their first treatment cycle, about 2/3 through the first and third treatment cycles (around day 22), prior to their sixth treatment cycle, and every three treatment cycles thereafter.

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 18 years of age or older
  • Radiographically measurable disease on contrast-enhanced MRI or CT images
  • Karnofsky Performance status of 60 or greater
  • Life expectancy of at least 3 months
  • Histologically confirmed diagnosis of recurrent or progressive intracranial meningioma(s). This includes benign, atypical, or malignant meningioma; patients with neurofibromatosis type 1 or 2 may participate. Participants without histological confirmation but a classic radiographic picture of meningioma may also enroll. Patients with neurofibromatosis type 2 and a classic radiographic picture of meningioma may also enroll without histological confirmation
  • At least ten unstained standard (4-5 micron) paraffin slides for immunohistochemistry. Participants who have not had a surgical procedure are exempt from this requirement
  • Unequivocal evidence for tumor progression by MRI (or CT scan if MRI is contraindicated)
  • MRI or CT must be performed within 14 days of registration
  • Patients with malignant meningiomas who require corticosteroids must be on a stable dose for at least 5 days prior to baseline imaging.
  • For patients who have been treated with external beam radiation, interstitial brachytherapy, or radiosurgery, an interval of 4 or more weeks must have elapses from the completion of radiation therapy to study drug administration, and there must be evidence of tumor progression.
  • There is no limit on the number of prior therapies

Exclusion Criteria:

  • Any cytotoxic chemotherapy, radiation, immunotherapy, or experimental therapy within 4 weeks prior to study drug administration
  • Prior therapy with somatostatin, andy somatostatin analogue, or any other hormonal treatment prescribed for the purpose of treating meningioma
  • Major surgery within 4 weeks prior to study drug administration
  • Malabsorption syndrome, short bowel or chologenic diarrhea not controlled by specific therapeutic means
  • Poorly controlled diabetes mellitus
  • Symptomatic cholelithiasis
  • Congestive heart failure, unstable angina, sustained ventricular tachycardia, ventricular fibrillation, clinically significant bradycardia, advanced heart block or a history of acute myocardial infarction within the six months preceding enrollment
  • QTc > 450 msec
  • Risk factors for Torsades de Pointes such as hypokalemia (< 3.5 mmol/L) not corrected by treatment, hypomagnesemia (< 0.7 mmol/L or < 1.6 mg/dL) not corrected by treatment, cardiac failure, clinically significant/symptomatic bradycardia, or high-grade AV block
  • Concomitant disease(s) that could prolong QT such as autonomic neuropathy (caused by diabetes, or Parkinson's disease), HIV, cirrhosis, uncontrolled hypothyroidism or cardiac failure
  • Concomitant medication(s) known to increase the QT interval within 4 weeks prior to study drug administration
  • Liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis with serum bilirubin > 2x ULN, serum albumin < 0.67 LLN, or ALT or AST more than 2 x ULN
  • Any other primary malignancy within the past 3 years (with the exception of basal cell carcinoma or carcinoma in situ of the cervix)
  • Active or suspected acute or chronic, uncontrolled infection or any history of immunocompromise, including any positive HIV test result
  • Abnormal coagulation studies (PT or PTT elevated by 30% above normal limits)
  • Use of anticoagulant medications (not including anti-platelet medications)
  • Lab values as specified in the protocol
  • Any current or prior medical condition that may interfere with the conduct of the study or the evaluation of its results in the opinion of the investigator
  • Pregnancy or lactation, or failure to practice a medically acceptable method of birth control
  • History of alcohol or drug abuse in the 6 month period before study enrollment
  • Participation in any clinical investigation with an investigational drug within 1 month prior to study drug administration
  • Known hypersensitivity to somatostatin analogues or any component of the pasireotide or octreotide LAR os s.c. formulations
  Contacts and Locations
Please refer to this study by its identifier: NCT00859040

United States, California
Cedars-Sinai Medical Center
Los Angeles, California, United States, 90048
United States, Illinois
Northwestern University
Chicago, Illinois, United States, 60611
United States, Massachusetts
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02115
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States, 02115
United States, New York
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
United States, North Carolina
Duke University Medical Center, Preston Robert Tisch Brain Tumor Center
Durham, North Carolina, United States, 27710
Wake Forest University Baptist Medical Center
Winston-Salem, North Carolina, United States, 27157
Sponsors and Collaborators
Patrick Y. Wen, MD
Brigham and Women's Hospital
Massachusetts General Hospital
Beth Israel Deaconess Medical Center
Memorial Sloan-Kettering Cancer Center
Wake Forest Baptist Health
Duke University
Cedars-Sinai Medical Center
Northwestern University
Principal Investigator: Patrick Y. Wen, MD Dana-Farber Cancer Institute
  More Information

No publications provided

Responsible Party: Patrick Y. Wen, MD, Directory, Center for Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center Identifier: NCT00859040     History of Changes
Other Study ID Numbers: 08-266, CSOM230CUS09T
Study First Received: March 9, 2009
Last Updated: October 29, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Dana-Farber Cancer Institute:
recurrent intracranial meningioma(s)
progressive intracranial meningioma(s)

Additional relevant MeSH terms:
Neoplasms, Nerve Tissue
Neoplasms by Histologic Type
Neoplasms, Vascular Tissue
Meningeal Neoplasms
Central Nervous System Neoplasms
Nervous System Neoplasms
Neoplasms by Site
Nervous System Diseases processed this record on April 23, 2014